» Articles » PMID: 34630130

Circulating MicroRNAs in the Second Trimester From Pregnant Women Who Subsequently Developed Preeclampsia: Potential Candidates As Predictive Biomarkers and Pathway Analysis for Target Genes of MiR-204-5p

Overview
Journal Front Physiol
Date 2021 Oct 11
PMID 34630130
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

MicroRNAs (miRNAs) play an important role in the pathophysiology of preeclampsia (PE). However, the expression of circulating miRNAs was not analyzed in the second trimester of pregnancy, a period of major relevance to identify predictive biomarkers for PE. Therefore, we examined the expression profiles of 84 circulating miRNAs using a PCR array in plasma collected between 20 and 25 weeks of gestation from pregnant women, who subsequently developed PE and those who remained healthy during pregnancy, randomly selected from a prospective cohort. Overall, 23 miRNAs had a fold change > 2.0 and were considered to be upregulated in plasma from pregnant women who subsequently developed PE, even before the onset of clinical symptoms of PE. However, only miR-204-5p was statistically significant ( = 0.0082). Experimentally validated interactions for the target genes of miR-204-5p extracted from miRTarBase were used in the gene set functional enrichment analysis to identify Reactome pathways. The network connecting the 37 target genes for miR-204-5p revealed pathways of known pathophysiological relevance during the early development of PE and included key genes related to PE, such as , and . We further depicted downstream targets of SIRT1 that are related to the vascular endothelial function or implicated in the pathophysiology of PE, namely, FOXO1, NFκB, HIF-1α, NOS3, and PPAR-γ. Our novel findings provide for circulating miRNAs upregulated in the second trimester on plasma from pregnant women who subsequently developed PE that is potentially related to the early development of PE, which may guide further studies focused on the validation of potential predictive biomarkers in PE.

Citing Articles

Potential epigenetic markers of clinical diagnostics/therapeutic targets in preeclampsia.

de Oliveira Cruz J, Luizon M Epigenomics. 2024; 16(15-16):1057-1060.

PMID: 39115080 PMC: 11418293. DOI: 10.1080/17501911.2024.2383558.


Identification of altered miRNAs and their targets in placenta accreta.

Murrieta-Coxca J, Barth E, Fuentes-Zacarias P, Gutierrez-Samudio R, Groten T, Gellhaus A Front Endocrinol (Lausanne). 2023; 14:1021640.

PMID: 36936174 PMC: 10022468. DOI: 10.3389/fendo.2023.1021640.


Systematic Review of the Diagnostic and Clinical Utility of Salivary microRNAs in Traumatic Brain Injury (TBI).

Hiskens M, Mengistu T, Li K, Fenning A Int J Mol Sci. 2022; 23(21).

PMID: 36361944 PMC: 9654991. DOI: 10.3390/ijms232113160.


A blood-based miRNA signature for early non-invasive diagnosis of preeclampsia.

Bao S, Zhou T, Yan C, Bao J, Yang F, Chao S BMC Med. 2022; 20(1):303.

PMID: 36096786 PMC: 9469544. DOI: 10.1186/s12916-022-02495-x.


Circulating microRNAs as Reliable Tumor Biomarkers: Opportunities and Challenges Facing Clinical Application.

El-Daly S, Gouhar S, Abd Elmageed Z J Pharmacol Exp Ther. 2022; 384(1):35-51.

PMID: 35809898 PMC: 9827506. DOI: 10.1124/jpet.121.000896.


References
1.
Choi S, Yun J, Lee O, Han H, Yeo M, Lee M . MicroRNA expression profiles in placenta with severe preeclampsia using a PNA-based microarray. Placenta. 2013; 34(9):799-804. DOI: 10.1016/j.placenta.2013.06.006. View

2.
Rocha-Penha L, Bettiol H, Barbieri M, Cardoso V, Cavalli R, Sandrim V . Myeloperoxidase is not a good biomarker for preeclampsia prediction. Sci Rep. 2017; 7(1):10257. PMC: 5579011. DOI: 10.1038/s41598-017-09272-4. View

3.
Sandrim V, Luizon M, Palei A, Tanus-Santos J, Cavalli R . Circulating microRNA expression profiles in pre-eclampsia: evidence of increased miR-885-5p levels. BJOG. 2016; 123(13):2120-2128. DOI: 10.1111/1471-0528.13903. View

4.
Sheridan R, Belludi C, Khoury J, Stanek J, Handwerger S . FOXO1 expression in villous trophoblast of preeclampsia and fetal growth restriction placentas. Histol Histopathol. 2014; 30(2):213-22. PMC: 4304873. DOI: 10.14670/HH-30.213. View

5.
Cudmore M, Ramma W, Cai M, Fujisawa T, Ahmad S, Al-Ani B . Resveratrol inhibits the release of soluble fms-like tyrosine kinase (sFlt-1) from human placenta. Am J Obstet Gynecol. 2011; 206(3):253.e10-5. DOI: 10.1016/j.ajog.2011.11.010. View